DE69732407D1 - Verfahren fuer die replikation von influenza in zellkultur und die bei diesem verfahren hergestellten influenza-viren - Google Patents

Verfahren fuer die replikation von influenza in zellkultur und die bei diesem verfahren hergestellten influenza-viren

Info

Publication number
DE69732407D1
DE69732407D1 DE69732407T DE69732407T DE69732407D1 DE 69732407 D1 DE69732407 D1 DE 69732407D1 DE 69732407 T DE69732407 T DE 69732407T DE 69732407 T DE69732407 T DE 69732407T DE 69732407 D1 DE69732407 D1 DE 69732407D1
Authority
DE
Germany
Prior art keywords
influenza
replication
cell culture
influenza viruses
viruses made
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69732407T
Other languages
English (en)
Other versions
DE69732407T3 (de
DE69732407T2 (de
Inventor
Albrecht Groener
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
GSK Vaccines GmbH
Original Assignee
Chiron Behring GmbH and Co KG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=7790127&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DE69732407(D1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Chiron Behring GmbH and Co KG filed Critical Chiron Behring GmbH and Co KG
Priority to DE122007000082C priority Critical patent/DE122007000082I1/de
Publication of DE69732407D1 publication Critical patent/DE69732407D1/de
Application granted granted Critical
Publication of DE69732407T2 publication Critical patent/DE69732407T2/de
Publication of DE69732407T3 publication Critical patent/DE69732407T3/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/145—Orthomyxoviridae, e.g. influenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5252—Virus inactivated (killed)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16151—Methods of production or purification of viral material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16211—Influenzavirus B, i.e. influenza B virus
    • C12N2760/16234—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Mycology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Apparatus Associated With Microorganisms And Enzymes (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
DE69732407.9T 1996-04-01 1997-04-01 Verfahren für die Replikation von Influenza in Zellkultur und die bei diesem Verfahren hergestellten Influenza-Viren Expired - Lifetime DE69732407T3 (de)

Priority Applications (1)

Application Number Priority Date Filing Date Title
DE122007000082C DE122007000082I1 (de) 1996-04-01 1997-04-01 Verfahren für die replikation von influenza in zellkultur und die bei diesem verfahren hergestellten influenza-viren

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
DE19612967 1996-04-01
DE19612967A DE19612967A1 (de) 1996-04-01 1996-04-01 Verfahren zur Vermehrung von Influenzaviren in Zellkultur, sowie die durch das Verfahren erhältlichen Influenzaviren
PCT/IB1997/000404 WO1997037001A1 (en) 1996-04-01 1997-04-01 Processes for the replication of influenza viruses in cell culture, and the influenza viruses obtainable by the process
EP97915628.8A EP0891420B2 (de) 1996-04-01 1997-04-01 Verfahren fuer die replikation von influenza in zellkultur und die bei diesem verfahren hergestellten influenza-viren

Publications (3)

Publication Number Publication Date
DE69732407D1 true DE69732407D1 (de) 2005-03-10
DE69732407T2 DE69732407T2 (de) 2006-01-19
DE69732407T3 DE69732407T3 (de) 2014-07-10

Family

ID=7790127

Family Applications (3)

Application Number Title Priority Date Filing Date
DE19612967A Withdrawn DE19612967A1 (de) 1996-04-01 1996-04-01 Verfahren zur Vermehrung von Influenzaviren in Zellkultur, sowie die durch das Verfahren erhältlichen Influenzaviren
DE69732407.9T Expired - Lifetime DE69732407T3 (de) 1996-04-01 1997-04-01 Verfahren für die Replikation von Influenza in Zellkultur und die bei diesem Verfahren hergestellten Influenza-Viren
DE122007000082C Pending DE122007000082I1 (de) 1996-04-01 1997-04-01 Verfahren für die replikation von influenza in zellkultur und die bei diesem verfahren hergestellten influenza-viren

Family Applications Before (1)

Application Number Title Priority Date Filing Date
DE19612967A Withdrawn DE19612967A1 (de) 1996-04-01 1996-04-01 Verfahren zur Vermehrung von Influenzaviren in Zellkultur, sowie die durch das Verfahren erhältlichen Influenzaviren

Family Applications After (1)

Application Number Title Priority Date Filing Date
DE122007000082C Pending DE122007000082I1 (de) 1996-04-01 1997-04-01 Verfahren für die replikation von influenza in zellkultur und die bei diesem verfahren hergestellten influenza-viren

Country Status (13)

Country Link
US (2) US20030119183A1 (de)
EP (3) EP1526172B1 (de)
JP (6) JP4447054B2 (de)
AT (2) ATE513905T1 (de)
CA (1) CA2250078C (de)
DE (3) DE19612967A1 (de)
DK (2) DK1526172T3 (de)
ES (3) ES2367081T3 (de)
HK (2) HK1075467A1 (de)
LU (1) LU91381I2 (de)
NL (1) NL300307I1 (de)
PT (2) PT891420E (de)
WO (1) WO1997037001A1 (de)

Families Citing this family (88)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19612966B4 (de) 1996-04-01 2009-12-10 Novartis Vaccines And Diagnostics Gmbh & Co. Kg MDCK-Zellen und Verfahren zur Vermehrung von Influenzaviren
WO1999023204A1 (en) * 1997-10-31 1999-05-14 Merck & Co., Inc. A method of improved mixing in roller bottles
EP1027426A4 (de) * 1997-10-31 2006-04-19 Merck & Co Inc Methode für verbessertes mischen einer varicella-infizierten zellkultur in rollflaschen
FR2775601B1 (fr) * 1998-03-03 2001-09-21 Merial Sas Vaccins vivants recombines et adjuves
AU3604201A (en) 2000-03-03 2001-09-12 Chemo Sero Therapeut Res Inst Cell usable in serum-free culture and suspension culture and process for producing virus for vaccine by using the cell
DE10144906B4 (de) * 2001-09-12 2013-11-28 Novartis Vaccines And Diagnostics Gmbh Verfahren zur großtechnischen Herstellung von Impfstoffen
WO2003072016A2 (en) * 2001-11-19 2003-09-04 Becton, Dickinson And Company Pharmaceutical compositions in particulate form
DE50211123D1 (de) 2002-09-16 2007-12-06 Pan Biotech Gmbh Verfahren zur kultivierung von zellen, insbesondere menschlicher oder tierischer zellen
ES2295418T3 (es) * 2002-09-16 2008-04-16 Pan-Biotech Gmbh Equipo para el cultivo de celulas, en especial de celulas humanas o de animales.
US7270990B2 (en) 2003-06-20 2007-09-18 Microbix Biosystems, Inc. Virus production
DE202005022108U1 (de) 2004-03-09 2013-11-12 Novartis Vaccines And Diagnostics, Inc. Influenza-Virus-Impfstoffe
CN101094915A (zh) * 2004-05-20 2007-12-26 益得生物医学公司 生产流感疫苗的方法
EP1766034B1 (de) 2004-05-21 2014-03-19 Novartis Vaccines and Diagnostics, Inc. Alphavirus-vektoren für impfstoffe gegen das influenza virus
EP2179744B1 (de) * 2004-09-09 2010-12-01 Novartis Vaccines and Diagnostics GmbH Verminderung von potentiellen iatrogenen Risiken in Verbindung mit Influenza Impfstoffen
US7510719B2 (en) 2004-12-08 2009-03-31 Medimmune, Llc Methods of producing influenza vaccine compositions
JP5414178B2 (ja) 2004-12-23 2014-02-12 メディミューン，エルエルシー ウイルス増殖用の非腫瘍形成性ｍｄｃｋ細胞株
FR2884255B1 (fr) 2005-04-11 2010-11-05 Vivalis Utilisation de lignees de cellules souches aviaires ebx pour la production de vaccin contre la grippe
CN101365480B (zh) 2005-11-01 2014-11-05 诺华疫苗和诊断有限两合公司 经由β-丙内酯处理的残留细胞DNA水平降低的细胞衍生病毒疫苗
US11707520B2 (en) 2005-11-03 2023-07-25 Seqirus UK Limited Adjuvanted vaccines with non-virion antigens prepared from influenza viruses grown in cell culture
CA2628424A1 (en) 2005-11-04 2007-05-10 Novartis Vaccines And Diagnostics S.R.L. Adjuvanted influenza vaccines including cytokine-inducing agents
WO2007052061A2 (en) 2005-11-04 2007-05-10 Novartis Vaccines And Diagnostics Srl Emulsions with free aqueous-phase surfactant as adjuvants for split influenza vaccines
US20090304742A1 (en) 2005-11-04 2009-12-10 Novartis Vaccines And Diagnostics Srl Influenza vaccines with reduced amount of emulsion adjuvant
NZ568211A (en) 2005-11-04 2011-11-25 Novartis Vaccines & Diagnostic Influenza vaccines including combinations of particulate adjuvants and immunopotentiators
PT2368572T (pt) 2005-11-04 2020-06-16 Seqirus Uk Ltd Vacinas com adjuvante dotadas de antigénios não-virião preparados a partir de vírus da gripe cultivado em cultura celular
KR20080089663A (ko) 2006-01-27 2008-10-07 노바티스 백신즈 앤드 다이아그노스틱스 게엠베하 운트 콤파니 카게 적혈구응집소 및 기질 단백질을 함유한 인플루엔자 백신
AU2007231027B2 (en) 2006-03-24 2013-10-03 Novartis Influenza Vaccines Marburg Gmbh Storage of influenza vaccines without refrigeration
AU2007245192B2 (en) 2006-03-31 2012-04-12 Wisconsin Alumni Research Foundation High titer recombinant influenza viruses for vaccines
WO2007132763A1 (ja) * 2006-05-11 2007-11-22 Juridical Foundation The Chemo-Sero-Therapeutic Research Institute インフルエンザウイルスの増殖方法
GB0614460D0 (en) 2006-07-20 2006-08-30 Novartis Ag Vaccines
AU2007297178B2 (en) 2006-09-11 2014-07-24 Novartis Ag Making influenza virus vaccines without using eggs
CN101627113B (zh) 2006-09-15 2013-04-24 米迪缪尼有限公司 支持病毒生长到高效价的mdck细胞系和采用该细胞系的生物反应器方法
WO2008068631A2 (en) 2006-12-06 2008-06-12 Novartis Ag Vaccines including antigen from four strains of influenza virus
CA2687122C (en) * 2007-05-04 2017-06-13 Baxter International Inc. Two-step temperature profile for the propagation of viruses
WO2008156778A2 (en) 2007-06-18 2008-12-24 Tokiko Watanabe Influenza m2 protein mutant viruses as live influenza attenuated vaccines
NZ582595A (en) 2007-06-27 2012-07-27 Novartis Ag Low-additive influenza vaccines
NZ587798A (en) 2008-03-18 2013-06-28 Novartis Ag Improvements in the preparation of influenza virus vaccine antigens utilising a phosphate buffer
CN102216450B (zh) 2008-09-24 2014-05-14 米迪缪尼有限公司 培养细胞、增殖和纯化病毒的方法
CN102307590A (zh) 2009-02-10 2012-01-04 诺华有限公司 具有减少量的角鲨烯的流感疫苗
WO2010092477A1 (en) 2009-02-10 2010-08-19 Novartis Ag Influenza vaccines with increased amounts of h3 antigen
CA2752039A1 (en) 2009-02-10 2010-08-19 Novartis Ag Influenza vaccine regimens for pandemic-associated strains
DE102010018462A1 (de) 2009-04-27 2011-04-07 Novartis Ag Impfstoffe zum Schutz gegen Influenza
KR101800245B1 (ko) 2009-05-21 2017-11-22 노파르티스 아게 비-내인성 ｐｏｌ ｉ 프로모터를 사용하는 역 유전학
WO2010144797A2 (en) 2009-06-12 2010-12-16 Vaccine Technologies, Incorporated Influenza vaccines with enhanced immunogenicity and uses thereof
CN102666860B (zh) 2009-07-31 2015-06-17 诺华股份有限公司 反向遗传系统
US20120237536A1 (en) 2009-09-10 2012-09-20 Novartis Combination vaccines against respiratory tract diseases
PL2491117T3 (pl) 2009-10-20 2014-05-30 Novartis Ag Udoskonalone sposoby odzyskiwania wirusa wykorzystujące odwrotną genetykę
WO2011056591A1 (en) 2009-10-26 2011-05-12 Warf - Wisconsin Alumni Research Foundation High titer recombinant influenza viruses with enhanced replication in vero cells
US20120309056A1 (en) 2010-02-04 2012-12-06 Leon Arnaud Fed-batch process using concentrated cell culture medium for the efficient production of biologics in eb66 cells
US10130697B2 (en) 2010-03-23 2018-11-20 Wisconsin Alumni Research Foundation (Warf) Vaccines comprising mutant attenuated influenza viruses
WO2011139717A1 (en) 2010-04-26 2011-11-10 Novartis Ag Improved production of virus replicon particles in packaging cells
JP5876036B2 (ja) 2010-05-21 2016-03-02 ノバルティス アーゲー インフルエンザウイルス再集合方法
PL2575873T3 (pl) 2010-06-01 2016-06-30 Novartis Ag Zatężanie i liofilizacja antygenów szczepionkowych grypy
HUE051711T2 (hu) 2010-06-01 2021-03-29 Seqirus Uk Ltd Influenzavakcina antigénjeinek koncentrálása liofilizálás nélkül
ES2531577T3 (es) 2010-08-20 2015-03-17 Novartis Ag Conjuntos de agujas para la administración de vacuna soluble contra la gripe
TR201903651T4 (tr) 2010-10-11 2019-04-22 Glaxosmithkline Biologicals Sa Antijen uygulama platformları.
ES2727836T3 (es) 2011-01-26 2019-10-21 Glaxosmithkline Biologicals Sa Régimen de inmunización del VRS
CA2829774C (en) 2011-03-14 2019-09-24 National Research Council Of Canada Method of viral production in cells
AU2012322704B2 (en) 2011-10-11 2017-09-07 Novartis Ag Recombinant self-replicating polycistronic RNA molecules
WO2013054199A2 (en) 2011-10-12 2013-04-18 Novartis Ag Cmv antigens and uses thereof
US20140248320A1 (en) 2011-10-20 2014-09-04 Novartis Ag Adjuvanted influenza b virus vaccines for pediatric priming
EP2820126B1 (de) 2012-03-02 2017-05-17 Seqirus UK Limited Reassortment von influenzaviren
EP2822585B1 (de) 2012-03-06 2017-05-17 Janssen Vaccines & Prevention B.V. Verbesserter impfstoff gegen grippe
JP2015526062A (ja) 2012-06-04 2015-09-10 ノバルティス アーゲー 改善された安全性試験
GB201218195D0 (en) 2012-10-10 2012-11-21 Istituto Zooprofilattico Sperimentale Delle Venezie Composition
BR112015012380A2 (pt) 2012-12-03 2017-09-12 Novartis Ag vírus influenza recombinante
AU2014229255B2 (en) 2013-03-13 2018-12-13 Novartis Ag Influenza B virus reassortment
JP2016521282A (ja) 2013-05-10 2016-07-21 ノバルティス アーゲー インフルエンザワクチンにおけるナルコレプシーのリスクの回避
DE202013005100U1 (de) 2013-06-05 2013-08-26 Novartis Ag Influenza Virus Reassortierung
DE202013005130U1 (de) 2013-06-05 2013-09-10 Novartis Ag Influenza Virus Reassortierung
EP3004332A2 (de) 2013-06-06 2016-04-13 Novartis AG Reassortment von influenzaviren
EP3022296B1 (de) 2013-07-15 2022-12-28 Wisconsin Alumni Research Foundation Rekombinante influenzaviren mit hohem titer und erhöhter replikation in mdck- oder vero-zellen oder eiern
WO2015196150A2 (en) 2014-06-20 2015-12-23 Wisconsin Alumni Research Foundation (Warf) Mutations that confer genetic stability to additional genes in influenza viruses
AU2015252119A1 (en) 2014-11-07 2016-05-26 Takeda Vaccines, Inc. Hand, foot, and mouth vaccines and methods of manufacture and use thereof
MA40920A (fr) 2014-11-07 2017-09-12 Takeda Vaccines Inc Vaccins de la main, du pied et de la bouche, et procédés de fabrication et d'utilisation de ceux-ci
US10633422B2 (en) 2015-06-01 2020-04-28 Wisconsin Alumni Research Foundation (Warf) Influenza virus replication by inhibiting microRNA lec7C binding to influenza viral cRNA and mRNA
WO2016207853A2 (en) 2015-06-26 2016-12-29 Seqirus UK Limited Antigenically matched influenza vaccines
US9890363B2 (en) 2015-07-06 2018-02-13 Wisconsin Alumni Research Foundation (Warf) Influenza virus replication for vaccine development
WO2017005880A1 (en) 2015-07-07 2017-01-12 Seqirus UK Limited Influenza potency assays
JP2019510481A (ja) 2016-02-19 2019-04-18 ウィスコンシン アルムニ リサーチ ファンデイション ワクチン開発のための改善されたｂ型インフルエンザウイルス複製
MY193736A (en) 2017-11-03 2022-10-27 Takeda Vaccines Inc Method for inactivating zika virus and for determining the completeness of inactivation
US11241492B2 (en) 2019-01-23 2022-02-08 Wisconsin Alumni Research Foundation (Warf) Mutations that confer genetic stability to genes in influenza viruses
US11851648B2 (en) 2019-02-08 2023-12-26 Wisconsin Alumni Research Foundation (Warf) Humanized cell line
US11390649B2 (en) 2019-05-01 2022-07-19 Wisconsin Alumni Research Foundation (Warf) Influenza virus replication for vaccine development
US20220211836A1 (en) 2019-05-08 2022-07-07 Takeda Vaccines, Inc. Inactivated virus compositions and zika vaccine formulations
EP4022046A2 (de) 2019-08-27 2022-07-06 Wisconsin Alumni Research Foundation (WARF) Rekombinante influenzaviren mit stabilisiertem ha zur replikation in eiern
MX2022006005A (es) 2019-11-18 2022-10-27 Seqirus Pty Ltd Metodo para producir virus de la influenza reagrupados.
KR102444684B1 (ko) * 2020-04-29 2022-09-16 에스케이바이오사이언스(주) 일회용 배양 공정 시스템을 이용한 인플루엔자 바이러스 생산 방법
WO2023154043A1 (en) 2022-02-09 2023-08-17 Takeda Vaccines, Inc. Zika vaccines and immunogenic compositions, and methods of using the same

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1278075B (de) * 1964-06-22 1968-09-19 Norden Lab Inc Verwendung von Gewebekulturen zur Zuechtung von Viren fuer die Gewinnung von Impfstoffen
US4064232A (en) * 1974-01-14 1977-12-20 Sandoz Ltd. Process for isolating the immunogenic components of influenza viruses
CA1122527A (en) * 1979-05-15 1982-04-27 Karen K. Brown Influenza vaccine production in liquid cell culture
USRE33164E (en) * 1979-05-15 1990-02-13 Mobay Corporation Influenza vaccine production in liquid cell culture
US4500513A (en) * 1979-05-15 1985-02-19 Miles Laboratories, Inc. Influenza vaccine production in liquid cell culture
US5013663A (en) * 1983-06-15 1991-05-07 American Home Products Corporation Canine corona virus vaccine
US4783411A (en) * 1984-10-22 1988-11-08 Janis Gabliks Influenza-A virus vaccine from fish cell cultures
US5762939A (en) * 1993-09-13 1998-06-09 Mg-Pmc, Llc Method for producing influenza hemagglutinin multivalent vaccines using baculovirus
US5824536A (en) * 1994-08-23 1998-10-20 St. Jude Children's Research Hospital Influenza virus replicated in mammalian cell culture and vaccine production
US5753489A (en) * 1994-11-10 1998-05-19 Immuno Ag Method for producing viruses and vaccines in serum-free culture
US5756341A (en) * 1994-11-10 1998-05-26 Immuno Ag Method for controlling the infectivity of viruses
US5646033A (en) * 1994-11-30 1997-07-08 Dyncorp African green monkey kidney cell lines useful for maintaining viruses and for preparation of viral vaccines
DE19612966B4 (de) * 1996-04-01 2009-12-10 Novartis Vaccines And Diagnostics Gmbh & Co. Kg MDCK-Zellen und Verfahren zur Vermehrung von Influenzaviren
US6514502B1 (en) * 1999-01-26 2003-02-04 Schering-Plough Veterinary Corporation Propagation of bovine cononavirus in chinese hamster ovary cells

Also Published As

Publication number Publication date
DK1526172T3 (da) 2011-10-03
PT1526172E (pt) 2011-09-01
WO1997037001A1 (en) 1997-10-09
EP2172543B1 (de) 2013-08-21
PT891420E (pt) 2005-06-30
CA2250078A1 (en) 1997-10-09
US20030119183A1 (en) 2003-06-26
ES2236799T3 (es) 2005-07-16
JP2010275321A (ja) 2010-12-09
NL300307I1 (nl) 2008-02-01
EP2172543A1 (de) 2010-04-07
EP0891420A1 (de) 1999-01-20
DE69732407T3 (de) 2014-07-10
US20070117131A1 (en) 2007-05-24
EP1526172A1 (de) 2005-04-27
JP2011212020A (ja) 2011-10-27
ATE513905T1 (de) 2011-07-15
EP1526172B1 (de) 2011-06-22
JP2006296437A (ja) 2006-11-02
DE122007000082I1 (de) 2009-01-02
HK1142093A1 (en) 2010-11-26
JP2008245659A (ja) 2008-10-16
EP0891420B1 (de) 2005-02-02
DK0891420T4 (da) 2014-01-20
ES2236799T5 (es) 2014-01-23
ATE288479T1 (de) 2005-02-15
DE19612967A1 (de) 1997-10-02
JP4447054B2 (ja) 2010-04-07
JP5264843B2 (ja) 2013-08-14
CA2250078C (en) 2009-06-23
ES2435726T3 (es) 2013-12-23
DK0891420T3 (da) 2005-04-25
DE69732407T2 (de) 2006-01-19
EP0891420B2 (de) 2013-11-20
JP2013116124A (ja) 2013-06-13
JP2000507825A (ja) 2000-06-27
HK1075467A1 (en) 2005-12-16
LU91381I2 (fr) 2008-01-30
ES2367081T3 (es) 2011-10-28

Similar Documents

Publication Publication Date Title
DE69732407D1 (de) Verfahren fuer die replikation von influenza in zellkultur und die bei diesem verfahren hergestellten influenza-viren
ATE482267T1 (de) Tierzellen und verfahren für die replikation von influenza viren
DE69111440D1 (de) Methoden und zusammensetzungen zur impfung gegen hiv.
ATE404587T1 (de) Verfahren zur identifizierung von induktoren und inhibitoren proteolytischer antikörper, zusammensetzungen sowie deren verwendungen
ATE481480T1 (de) Methoden und zusammensetzungen zur herstellung von polypeptiden
DK0922102T3 (da) Receptor-agonister af hepatocyt-vækstfaktor og anvendelser deraf
BR9707948A (pt) Processo para obter plantas transplastômicas
BR0207775A (pt) Lipossomos anfotéricos métodos para carregamento dos mesmos com ingredientes ativos e sua utilização
GR890100846A (el) Μεθοδος μετατροπης κυτταρικης διαφοροποιησης και λειτουργιας καισυνθεσεις της.
DE59507481D1 (de) Verfahren zur Herstellung von aliphatischen alpha, omega-Diolen
DE69005987D1 (de) Dichtung, Vorrichtung und Verfahren zur ihrer Herstellung.
DE3877711D1 (de) Antibeschlagzusammensetzung, damit beschichtetes produkt und verfahren zu dessen herstellung.
DE69009614D1 (de) Verfahren zur Herstellung von (S)-gamma-Hydroxymethyl-alpha,beta-Butenolid.
DE3576361D1 (de) Rekombinante dna, damit transformierter mikroorganismus, und verfahren zur herstellung von menschlicher cu-zn superoxiddismutase unter verwendung des transformierten mikroorganismus.
DE59001156D1 (de) Verfahren zur herstellung von muscon, zwischenprodukte fuer dieses verfahren sowie deren herstellung.
DE60024997D1 (de) Vgf polypeptide und verfahren zur behandlung von vgf-erkrankungen
DE69013132D1 (de) Verfahren zur Herstellung von Octa-2,7-dien-1-ol.
DE60136558D1 (de) Verfahren zur kultivierung humaner chondrozyten
BR0114884A (pt) Compostos calcilìticos
KR950700988A (ko) 미생물, 이들의 제조방법 및 이들의 사용(Micro-organisms, preparation method therefor and uses thereof)
ATE231486T1 (de) Optisch aktive 2-amino-tetraline, verfahren zu ihrer herstellung und pharmazeutische zusammensetzungen die diese enthalten und die nützlich sind zur vorbeugung und behandlung von septischem schock
ATE34386T1 (de) 1,2,3,4-tetrahydro-1-aminomethyl-4-phenylisochinoline und verfahren zu ihrer herstellung.
DE69008488D1 (de) Verfahren zur Herstellung von N-Alkylaminophenolen und von N,N-Dialkylaminophenolen.
DE58906998D1 (de) Verfahren zur Herstellung von 4,5,6-Trichlorpyrimidin.
DE69102611D1 (de) Verfahren zum Gerben von Proteinsubstanzen, insbesondere pflanzliche Proteinsubstanzen sowie ölige Proteine und nach diesem Verfahren hergestellte gegerbte Proteinsubstanzen.

Legal Events

Date Code Title Description
8363 Opposition against the patent
V448 Application of spc

Free format text: PRODUCT NAME: INFLUENZA-IMPFSTOFF, DER AUS EINEM IN ZELLKULTUR ANGEZUECHTETEN INFLUENZA-VIRUS HERGESTELLT WIRD,WOBEI DIE ZELLEN FUER DIE VIRUSREPLIKATION BEI EINER TEMPERATUR IM BEREICH VON 30-36 GRAD C. KULTIVIERT WERDEN; REGISTRATION NO/DATE: EU/1/07/394/001 - EU/1/07/394/006; 20070601

Spc suppl protection certif: 12 2007 000 082

Filing date: 20071130

8327 Change in the person/name/address of the patent owner

Owner name: NOVARTIS VACCINES AND DIAGNOSTICS GMBH & CO. K, DE

V454 Spc application withdrawn or to be regarded as withdrawn

Free format text: PRODUCT NAME: INFLUENZA-IMPFSTOFF, DER AUS EINEM IN ZELLKULTUR ANGEZUECHTETEN INFLUENZA-VIRUS HERGESTELLT WIRD,WOBEI DIE ZELLEN FUER DIE VIRUSREPLIKATION BEI EINER TEMPERATUR IM BEREICH VON 30/36 GRAD C. KULTIVIERT WERDEN; REGISTRATION NO/DATE: EU/1/07/394/001 - EU/1/07/394/006; 20070601

Spc suppl protection certif: 12 2007 000 082

Filing date: 20071130

8327 Change in the person/name/address of the patent owner

Owner name: NOVARTIS VACCINES AND DIAGNOSTICS GMBH, 35041 , DE